Pharmaceutical Outcomes Research & Policy Program (PORPP) 2017 ANNUAL REPORT

From the Director, Anirban Basu August 2, 2017

The 2017 Annual Report has a special place in the twenty-one-year history of PORPP, for it is the very last report under this designation. After two years of conversations with our faculty, students, alumni, advi-sors and friends, and a full strategic planning process we have been approved for transitioning into an Institute status within the University. The formal launch of The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute will happen later this Fall. We thank our Chair, Steve White, and our Dean, Sean Sullivan for their unwaver-ing support throughout the process. An Institute designation will better reflect the breadth of work conducted by our faculty, students, and post-docs. It will promote the recognition of PORPP and become an international hub of excellence in the broad-er areas of health outcomes research, pharmacoepidemiology, health

economics, and policy. This endeavor will also reinforce the crucial role of medications in shaping patient health and patient-centered health care delivery. In fact, the current PORPP faculty is al-ready engaged in a range of activities that traverses these broader domains. Importantly, develop-ing junior faculty into world-class researchers in focused areas is essential for training the next generation of scientists in our graduate program

The institute-level designation will also allow us to organize research and training activities and resources into focused Programs to enhance our competitiveness and expand our leadership in the field. Key programmatic areas that have been identified to date include health economics, poli-cy analysis/big data science, individualized care, drug and vaccine safety, and global medicines issues.

The Institute will be an integral part of the Department of Pharmacy and the School of Pharmacy. We believe our focused research programs will facilitate interactions with clinical faculty in the De-partment and the School of Pharmacy.

Our usual bouts of excellence, nevertheless, continues. This annual report highlights some of those accomplishments and special moments. For this coming year, we are admitting another strong new graduate program cohort. The admissions committee has recruited our top candidates, who are profiled here. Our Distance Learning Certificate in Health Economics and Outcomes Re-search will welcome another large batch of students this fall. We have now trained over 300 stu-dents through this mechanism. This past year we opened a faculty search, led by Dave Veenstra, for a Research Assistant Pro-fessor position with a focus on Health Economics and Policy. Also, we congratulate Lou Garrison for his leadership as the President of ISPOR last year. He will continue to be a resource and men-tor for the incoming ISPOR President, and one of our alumni, Shelby Reed. Finally, as many of you know Penny Evans, our long-time Graduate Program Advisor, retired this year. We will be ever thankful for her contributions to the program and her dedication to our stu-dents. In recognition, we have renamed the UW ISPOR Student Chapter Fund as the Penny Ev-ans UW ISPOR Student Chapter Support Fund. We also welcome our new Graduate Program Advisor/Program Operations Specialist, Michelle Hughes, who has seamlessly transitioned into her new role with excellent training from Penny. I also want to thank Paul Kraegel, our other Program Operations Specialist, for the excellent support he provides to our program. We remain grateful to PORPP’s founding members, alumni and corporate advisors, whose contin-ued support is instrumental to our success. I thank all of our past and present Corporate Advisory Board members for their continued support to the program. We cherish their engagement with the program, and in the future with the Institute.

Pharmaceutical Outcomes Research & Policy Program

Department of Pharmacy, University of Washington

Box 357630, Seattle, WA 98195-7630 Phone: 206-616-1383

Fax: 206-543-3835 Email: mahughes@uw.edu

http://sop.washington.edu/porpp

PORPP Faculty

Joseph Babigumira, MBChB, MS, PhD Adjunct Assistant Professor

Aasthaa Bansal, PhD Research Assistant Professor

Anirban Basu, PhD Stergachis Family Endowed Director & Professor, Pharmaceutical Outcomes Research & Policy Program

Brian Bresnahan, PhD Adjunct Research Assistant Professor

Josh Carlson, MPH, PhD Associate Professor, Associate Director, Graduate Programs

Beth Devine, PharmD, MBA, PhD Associate Professor, Director, Graduate Programs

David Flum, MD, MPH Adjunct Professor

Louis Garrison, Jr., PhD Professor Emeritus Shelly Gray, PharmD, MS Shirley & Herb Bridge Endowed Professor

Ryan Hansen, PharmD, PhD Research Assistant Professor

Thomas Hazlet, PharmD, DrPH Associate Professor Lurdes Inoue, MS, MS, PhD Adjunct Professor

Jerry Jarvik, MD, MPH Adjunct Professor

Larry Kessler, ScD Adjunct Professor

Gary Lyman, MD, MPH Adjunct Professor Co-Director, HICORE (Hutchinson Institute for Cancer Outcomes Research and Evaluation), Fred Hutchinson Cancer Research Center

Zachary Marcum, PharmD, MS, PhD Bailey Faculty Fellow Assistant Professor

Donald Patrick, PhD Adjunct Professor, Dept. of Health Services

Scott Ramsey, MD, PhD Adjunct Professor, Director, HICORE (Hutchinson Institute for Cancer Outcomes Research and Eval-uation), Fred Hutchinson Cancer Research Center

Andy Stergachis, PhD Professor, Associate Dean for Research, Graduate Education & New Initiatives

Sean Sullivan, PhD, Dean of the School of Pharmacy

David Veenstra, PharmD, PhD Professor, Associate Director, PORPP

Davene Wright Assistant Professor, Pediatrics Adjunct Assistant Professor, Pharmacy

Staff Penny Evans Graduate Program Advisor Michelle Hughes Graduate Program Advisor Paul Kraegel, MSW Program Operations Specialist

Editors, Writers: Michelle Hughes, Penny Evans, Sarah C.B. Guthrie Designers: Michelle Hughes, Sarah C.B. Guthrie Photographer: Alex Levine Contributors: Anirban Basu, Josh Carlson, Beth Devine, Ryan Hansen, Andy Stergachis, Sean Sullivan, Dave Veenstra

Student Support Fund Named After Award-Winning PORPP Administrator Penny Evans By Sarah C.B. Guthrie

In the spring 2017 PORPP alumni newsletter, Director Anirban Basu announced the establishment of The Penny Evans UW In-ternational Society for Pharmacoeconomics and Outcomes Re-search (ISPOR) Student Chapter Support Fund.

This fund, named in honor of our highly-esteemed, award-winning program administrator, Penny Evans, will support student activi-ties for our ISPOR chapter.

Penny retired in June 2017, but her influence and excellence re-main forever imprinted on our program—and is now encapsulated in this fund.

The students and alumni of the PORPP program know first hand how important Penny has been to the growth and excellence of this globally-renowned program.

“As we enter a new chapter in our evolution as a program,” says Anirban, “I hope you will consider a gift to The Penny Evans ISPOR Student Chapter Support Fund and lead the way in fostering the exceptional talent and innovation of our students.”

For more information on how to donate, please visit: Bit.ly/PennyFund

Penny Evans, award winning PORPP Administrator, retired in June 2017.

A Warm Welcome to PORPP’s Newest Staff Member

As of March, Michelle Hughes is now the program operations special-ist and graduate program advisor. Over the past few months, she has worked closely with Penny Evans to make this transition as seamless as possible for faculty and students. Michelle started with the depart-ment of pharmacy 1 year ago and is excited to work with PORPP’s students, post-docs and faculty in the upcoming academic year. Be-fore starting at the UW, Michelle completed a year of service with AmeriCorps in Federal Way, WA. Her hobbies include cooking, participating in local cooking classes, volunteering at community farm to table operations, backpacking, hiking and being outdoors. Stop by the department and say hi to Michelle!

3

Master of Science in Pharmacy Degrees

Laura Hart, PharmD, MS Thesis: "Evaluating the Association Between Central Nervous System (CNS)-Active Medications and Falls in Older Adults with Dementia” Advisor: Zachary Marcum, PharmD, PhD Harry Lee, PharmD, MS Thesis: “Cost-Effectiveness of Pembrolizumab for Advanced NSCLC with Performance Based Risk Sharing Agreements” Advisor: David Veenstra, PharmD, PhD Michael Serbin, PharmD, MS Thesis: “Assessing the Societal Burden of Glaucoma Patients Not Suitable for Topical Medication Therapy” Advisor: Beth Devine, PharmD, MBA, PhD Sheila Shapouri, PharmD, MS Thesis:“Predicting Hospitalizations Post-Discharge Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)” Advisor: Beth Devine, PharmD, MBA, PhD Lucille Sun, PharmD, MS Thesis: “Risk of Depressive or Anxiety Disorders in Commerically Insured Patients with Non-Hodgkin Lym-phoma in the US: A Retrospective Analysis” Advisor: Josh Carlson, MPH, PhD

Doctor of Philosophy in Pharmacy Degrees Solomon Lubinga, MSc, PhD Dissertation: “Demand for Voluntary Medical Male Cicumcision for HIV Prevention: the Influence of Economic and Psychological Factors, and Policy Implications” Advisor: Anirban Basu and Joseph Babigumira Elisabeth Vodicka, MHA, PhD Dissertation: “Cervical Cancer in Low-Income Settings: Costs and Cost-Effectiveness of Screening and Treatment” Advisors: Joseph Babigumira and Brian Bresnahan

NEW ALUMNI

CLASS OF 2017

4

Lauren Chin, PharmD, UW/Bayer Post-Doctoral Fellow 2017-2019 Lauren received her PharmD from the University of Washington, School of Pharmacy in 2017 and a BS in Biological Sciences from the University of South-ern California in 2012. Her interests include eco-nomic modeling, comparative effectiveness re-search, formulary management, and statistical anal-yses. During her time in pharmacy school, Lauren assisted Dr. Beth Devine with research projects regarding the clinical use of pharmacogenomic (PGx) biomarker testing and PGx evidence provid-ed in FDA drug labels. She competed in AMCP’s

P&T competition for three consecutive years, and as a third year, her team was selected to compete nationally. As a fourth year, Lauren completed an 8-week externship in Allergan’s Global Health Economics and Outcomes Research department. At Allergan, she developed an economic model with sensitivity analyses to estimate the economically justifiable price of a novel intervention, conducted a targeted literature review, and completed addi-tional projects involving patient- and clinician-reported outcomes to inform internal discussions.

Samantha Clark, MS, PhD Student Samantha joins PORPP from the International Vac-cine Access Center at Johns Hopkins where she worked as a health economist conducting economic and health outcomes research. Her projects focused on the development of decision-analytic models to assess the impact of immunization from a variety of stakeholder perspectives. She received her mas-ter’s degree in health economics from the Johns Hopkins Bloomberg School of Public Health in 2013 and her bachelor’s in economics from St. Mary’s College of Maryland in 2008. Her research interests

include heath economics, decision sciences, healthcare disparities, and methods in comparative effectiveness research. Samantha is excited for the opportunity to continue to learn advanced research and modeling tech-niques from PORPP faculty. Her research interests include: health eco-nomics, decision sciences, healthcare disparities and comparative effec-tiveness research

Karen (He) Guo, MSc, MPP, PhD Student Karen recently received her Master of Public Policy (MPP) degree from The University of Chicago. Prior to UChicago, she has been working in the HEOR and market access at Johnson & Johnson and IMS Health for five years after she received the MSc. in International Health Policy (Health Economics track) at The London School of Economics in 2010. She has experienced and managed a broad rang of pro-ject types, including health economic modeling, mar-ket access value dossiers, product value proposition, pricing strategy, competitors’ landscape, and sys-tematic literature review. In addition, Karen has worked as an analyst in World Health Organization

based in Geneva, focusing on vaccine strategy and health financing pro-jects. Her research interests include cost effectiveness analysis; health policy; health service evaluation and outcomes research. She is excited to join the PORPP family.

Sara Higa, MS, PharmD, UW/Allergan Post-Doctoral Fellow 2017-2019 Sara received her PharmD from the University of Maryland Baltimore and her BS and MS degrees from Georgetown University. Before joining PORPP, she worked with faculty on various research projects ranging from qualitative case studies to retrospective claims database analyses. Her involvement in the Pharmaceutical Health Services Research Depart-ment at the University of Maryland was instrumental in fostering her passion and experience in outcomes research. She is excited to work with the PORPP and Allergan teams to learn more about the utility of

health economics and outcomes research in health care. Her research interests include health economics, policy, comparative effectiveness, and patient-centered outcomes.

WELCOME TO OUR NEW STUDENTS AND FELLOWS

Chiemeka Ike, MPH, PharmD, UW/Allergan Post-Doctoral Fellow 2017-2019 Chiemeka received her PharmD degree from the University of Houston College of Pharmacy in 2017. Her interest in the pharmaceutical industry propelled her to start an Industry Pharmacists Organization (IPhO) chapter at the University of Houston to create awareness and spark interest among pharmacy students. HEOR sparked her interest particularly because she sought to com-bine her PharmD and epidemiology background in a pharmaceutical industry career focused on health outcomes. Chiemeka completed clinical

clerkships in managed care, cardiology, and at the U.S. Food and Drug Administration (FDA) Department of Pediatric Clinical Pharmacology. Prior to pharmacy school, she worked in clinical guideline development at the American Society for Radiation Oncology (ASTRO). In addition, she obtained a Master of Public Health in Epidemiology at the George Wash-ington Milken Institute School of Public Health. Her research interests include infectious disease and oncology.

Tricia Rodriguez, MPH, PhD Student Tricia joins PORPP from the University of Wash-ington’s Department of Global Health, in the Health Metrics and Evaluation program. During her MPH, Tricia’s thesis work focused on the cost-effectiveness of palliative care for women with breast cancer in Uganda. She also served as a research assistant at I-TECH, where she evaluated the impact of ART prescribing interval length on retention and viral suppression for patients with HIV in Haiti. Prior to her MPH, Tricia was a senior consultant at a management consulting firm, where she worked with payers on impact and strategy

related to the Affordable Care Act, particularly risk adjustment in commer-cial markets. Tricia received a B.S. in economics from DePaul University. She is interested in research in the economics of end-of-life and palliative care.

Enrique Saldarriaga, MS, PhD Student Enrique studied economics and epidemiology in Peru. For the last four years he has been working on health economics research. In the last year he started to work on public policy and public man-agement projects. Currently he is working at the Ministry of Health in Peru, developing a tool for monitoring facilities resources and productivity management, with the objective to improve the quality of the healthcare provision. His final objec-tive is to improve the Developing countries' health system through better decision making processes, based on scientific data. His research interests

include economic evaluation to improve policy making processes, public resource management in the health sector and reducing access barriers to health care.

5

The 2017 PORPP Retreat focused on the themes of diversity, equity and inclusion. Anu Taranath, PhD, Department of English, UW, led the group through a workshop focusing on diversity, equity and inclusion. Her engaging presentation and approach helped everyone in the room reflect on what PORPP is doing well and what the program can improve upon moving forward. She asked insightful questions and pushed for meaningful, honest discussion among the students, faculty and staff. Action items identified through collaborative discussion between faculty and students: Have students identify faculty research areas within the first year and begin working with them

as soon as possible Establish a clear process for TA and RA opportunities as they become available Prepare students for the transition from the second year to the third year, especially when it

comes to funding Create an Alumni group on LinkedIn for networking and job openings Hold regular student and faculty lunches as a way to connect everyone in the program and

learn about new opportunities, research areas and to build stronger, lasting relationships.

2017 PORPP RETREAT

After the retreat, PORPP students, post-docs, faculty, staff, family (and 4-legged friends!) came to celebrate! Los Chilangos taco truck served up some tasty grub throughout the night.

6

CURRENT GRADUATE STUDENTS AND FELLOWS

Blythe Adamson, MPH; PhD Candidate Blythe continues her dissertation research on im-plementation strategies for HIV treatment and pre-vention. In August, she travels as a U.S. delegate to the Lindau Nobel Laureate Meeting in Germany where she will present her findings to 19 Nobel Prize winners in Economics. After serving as Presi-dent of the UW ISPOR Student Chapter, she was selected by the ISPOR Presidents at other univer-sities to lead as the ISPOR Student Network Chair in 2017-2018. In collaboration with a UW bioengi-neering lab, Blythe submitted a provisional patent

application for a diagnostic platform technology that received several awards for innovation.

Mark Bounthavong, PharmD, MS; PhD Candidate Mark Bounthavong will be a fifth-year PhD candi-date in PORPP who also works as the national data program manager for the Department of Vet-erans Affairs (VA) National Academic Detailing Service. His dissertation evaluates the impact of academic detailing on naloxone prescribing and explores the facilitators and barriers to the adop-tion of key messages associated with Opioid Over-dose Education and Naloxone Distribution. He

received his PharmD from Western University of Health Sciences and his MPH from Emory University. Prior to his doctoral studies, Mark worked as a pharmacoeconomist at the VA San Diego Healthcare Sys-tem.

Elizabeth “Lizzy” Brouwer, MPH; PhD Student Elizabeth spent her second year in PORPP com-pleting core program coursework, acting as Sec-retary for the UW ISPOR Student Chapter, and passing her final preliminary exams. Since June 2016, she worked as a Research Assistant on the ICER grant with Dr. Josh Carlson, supporting models for Multiple Sclerosis, Atopic Dermatitis, and Multiple Myeloma medications and present-ing a poster on MS medication adherence at the 2017 Annual ISPOR meeting in Boston. Elizabeth

wrapped up a consulting project in January 2017 with RTI International and the World Health Organization assessing return on investment for policies addressing non-communicable diseases in Mongolia. During the Spring of 2017, Elizabeth completed an internship at PATH regard-ing the costs of self-injectable contraceptive technology in three sub-Saharan Africa countries. This summer, Elizabeth will work with PORPP alumnus, Dr. Kai Yeung, at the Kaiser Permanente Research Institute on trends in value-based insurance formularies, as well as continuing her work on the ICER grant. She will spend her third year working on her short proposal, which will explore opportunities to inte-grate cost-effectiveness analysis and decision-making analysis in US health policy.

Shuxian Chen MA; PhD Student Shuxian is entering her second year in the PhD program in PORPP. During the first year, she has finished part of the coursework, while also working with Professor Josh Carlson as an RA on perfor-mance-based risk-sharing (PBRS) arrangements and updating the database. In the second year, she will complete her coursework and at the same time work with several faculty on the Health Tech Project with a focus on developing and applying novel real-world data methods.

Devender Dhanda, BSPharm, MS; PhD Candidate Devender will be entering his fifth year of the PhD program in PORPP. During his fourth year, Devender completed his course-work requirements and worked with Dr. Dave Veenstra on the Person-alized Medicine Economics Research (PRiMER) grant. Devender recently presented his work at In-ternational Health Economics Association meeting (iHEA) at Boston. His work on evidence comparison between the pharmacogenomics-based and clinical-

based decisions for warfarin dosing was published in Clinical Pharmacolo-gy and Therapeutics. Devender recently passed his general exam for PhD candidacy and is working on his dissertation “Innovation, Value, and Un-certainty in Oncology Precision Medicine”.

Horacio Duarte, MD; MS Student Horacio is entering his 3rd year as a master’s de-gree student in PORPP and is an acting instructor in pediatric infectious diseases at the University of Washington/Seattle Children’s Hospital. Horacio earned a B.A. in biological anthropology from Har-vard College, an M.D. from the University of Texas Medical School at Houston, and he completed his pediatrics residency and pediatric infectious diseas-es fellowship at Seattle Children’s Hospital. He is interested in economic evaluation of global health programs, with a special interest in HIV and child

health. Currently, Horacio is studying the cost-effectiveness of HIV drug resistance testing in Kenya. Research interests include cost-effectiveness analysis, infectious disease modeling, global health, HIV, and children’s health.

Simrun “Simi” Grewal, MHS; PhD Student During her third year in the PhD program, Simi en-joyed working with Dr. Josh Carlson and colleagues on the Personalized Medicine Economics Research (PriMER) project. As an RA on PriMER, she has as-sisted on developing discrete choice experiment sur-veys to explore preferences for genetic testing from different stakeholder perspectives. The team’s work has been accepted for a poster presentation at the Society for Medical Decision Making (SMDM) confer-ence in October. Additionally, Simi has provided research support to two key initiatives led by the Inter-

national Society for Pharmacoeconomics and Outcomes Research (ISPOR) on Vaccine Economic Evaluation and Value Assessment Frame-works. Entering her fourth year, Simi is excited to continue learning in her research roles while exploring the next stages of her dissertation proposal.

Shalak Gunjal, MS; PhD Student Shalak is entering the second year of his PhD program. During the past year, he worked as a teaching associate for the Biomedical Regulatory Affairs program. Additionally, he provided research support and co-authored two evidence reports led by the AHRQ - Mayo Clinic Evidence-Based Prac-tice Center on the clinical utility of fractional ex-haled nitric oxide in asthma management and comparative effectiveness and safety of treatments for childhood anxiety disorders. Currently, he is the Global Product Strategy Intern in the Global Pric-ing & Market Access Oncology division at Genen-tech working on personalized reimbursement mod-

el-enabled combination price assessment for third line colorectal cancer and multiple myeloma treatments across key EU markets. During his sec-ond year, Shalak plans on completing the core coursework and commence on identifying his dissertation research.

7

CURRENT GRADUATE STUDENTS AND FELLOWS, CONT.

Nathaniel Hendrix, PharmD; PhD Student Nathaniel is entering his third year in PORPP’s PhD program. During the past year, he finished his coursework, having especially enjoyed classes in data science and econometrics. In the fall, he worked with PORPP Professor David Veenstra on a cost-effectiveness model for immunomodu-lators for treatment of psoriasis. They and their collaborators at the Institute for Clinical and Economic Review reported on their

work at the ISPOR General Meeting in Boston. Over the winter and spring, he has worked with Associate Professor Josh Carlson to determine how value of information analyses could be used during the grant review process of a major cancer consortium. In the com-ing year, he intends to explore his interests in the economic and clinical impacts of machine learning in the first stages of his disser-tation.

Erik Landaas, MPH; PhD Student Erik is entering the second year of his PhD program. Erik completed his MPH from the UW, and before coming to PORPP, he was working in Hawaii as the Chief of Outcomes and Compliance at the Department of Health. During the past year, he has com-pleted a portion of his coursework and de-veloped more sophisticated scientific meth-ods skills. He began working with UWMC’s Office of the Medical Director and Dean

Sullivan on UWMC’s Smart Innovation – a hospital based health technology assessment program. UWMC is utilizing Erik’s evidence criteria model from a paper he recently published to determine coverage for new and emerging medical technologies for WA State public payers. Erik plans on assisting in the implementation and lead an evaluation of the Smart Innovation Program.

Harry Lee, PharmD, MS Harry received his PharmD degree from the University of Washington in 2016, and com-pleted his mater of science in pharmaceuti-cal outcomes and health policy this year. His graduate thesis was focused on the use of performance-based risk sharing arrange-ments in a case study of first line pembroli-zumab therapy for advanced non-small cell lung cancer. He hopes to continue his work in this area to promote the use and evalua-tion of novel pricing and reimbursement

schemes so patients may receive timely and consistent access to care and achieve optimal health outcomes.

Meng Li, ScM; PhD Student Meng is entering her fifth year in the PhD program. During the past year, she has been working on her dissertation, which is examin-ing the real options value of life and innova-tion. She has also been working with several faculty members on a number of research projects, including establishing a framework for examining the value of information of heart failure clinical trials, validating a new instrument that measures the psychological impact associated with genetic testing, exam-ining the utilization patterns of opioid in

Washington State, and, examining the acceptability and perfor-mance of using visual inspection for cervical cancer screening in resource-limited settings.

Solomon J Lubinga, BPharm, MSc, PhD Solomon just completed his PhD in PORPP as of August 2017. He is interested in the application of decision theories from economics and psychol-ogy to individual decision-making for preventative health care. His Dissertation examined the eco-nomic and psychological factors influencing the demand for medical male circumcision for HIV prevention. As a postdoctoral fellow, Solomon will be mentored by Dr. Ryan Hansen.

Michael Serbin, PharmD; UW/Allergan Post-Doctoral Fellow 2016-2018 Michael received his PharmD degree from the University of Washington School of Pharmacy in 2016 and a BS in biomedical engineering from the University of Southern California in 2011. At UWSOP he worked as a research assistant for Dr. Veenstra. In his first year as a UW/Allergan Fellow Michael worked with the GHEOR eye care team at Allergan to develop a thesis titled “Assessing the Societal Burden of Glaucoma Patients With vs. Without Physical or Mental

Comorbidities“ which he will be submitting for publication as soon as he can. This year Michael is excited to start working in Irvine, California at the Allergan offices as he transitions out of life in a classroom.

Sheila Shapouri, PharmD; UW/Allergan Post-Doctoral Fellow 2016-2018 Sheila is entering her 2nd year of the UW/Allergan fellowship. Prior to the fellowship she received her PharmD from the University of Washington in 2016. Over the past year, Sheila has been taking coursework and working on her master's thesis model for "Predicting Hospitaliza-tions Post-Emergency Department Discharge Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)." She also presented a poster at the ISPOR 22nd Annual

International Meeting entitled "Cost-Utility Analysis of Outpatient Dal-bavancin for ABSSSIs versus Inpatient Vancomycin." Sheila is looking forward to continuing her research and working on-site in the infectious disease therapeutic area with the Global Health Economics and Out-comes Research team at Allergan.

Kangho Suh, PharmD, MS; PhD Student Kangho is entering his fourth year in the PhD program in PORPP. In the past year he was working as a RA for Dr. Anirban Basu on a pro-ject with Kaiser Permanente using comparative effectiveness methods (instrumental variables and propensity score matching) to compare bariatric surgical procedures. He will continue in this role this upcoming year. Kangho also worked with Dr. Aasthaa Bansal on an inde-pendent study assessing adherence to and ef-

fectiveness of surveillance tests after surgery for colorectal cancer patients. Kangho plans on finalizing a dissertation topic and advancing through the process in the upcoming year.

8

CURRENT GRADUATE STUDENTS AND FELLOWS, CONT.

Elisabeth Vodicka, MPH; PhD Candidate Elisabeth recently finished her 4th year in PORPP. Last year focused on continuing her dissertation work on cervical cancer/health services integration in Kenya and Uganda under the mentorship of her chair (Joseph Babigumira) and committee mem-bers (Michael Chung, Lou Garrison and Andy Stergachis). Along with colleagues Will Canestaro, Don Downing, and James

Trussell (Princeton University), Elisabeth published an op-ed in the Seattle Times related to their economic analysis of em-ployer-mandated contraception coverage in the U.S. She con-tinued collaborating with researchers at Universidad Peruana Cayetano Heredia in Peru to assess the potential for private pharmacies to offer point-of-care screening for non-communicable diseases.

Wei-Jhih Wang, MS; PhD Student Wei-Jhih is entering her third year in PORPP, and completed the required coursework. Last year, she worked with Dr. Carrie Bennette and completed data man-agement for several public data sources to explore the relationship between character-istics of geographic area and clinical trials. Her independent study is working with Dr. Anirban Basu on the topic of seizure after stroke, and developing a new method for

meta analyzing count data over varying duration which is nom-inated for ISPOR research poster presentation award. This summer, she will continue to work on a value of information project as a research assistant, and she is also working with Dr. Aasthaa Bansal for a project on machine learning.

Lauren Strand, MS; PhD Student Lauren is entering her second year in the program. Over the past year, she has completed coursework, written two prelim-inary exams, and built her first cost-effectiveness model in clinically isolated syndrome with guidance from Drs. Josh Carlson, Ryan Hansen, and Marita Zim-mermann. She presented this work at the ISPOR conference in her hometown of Boston, where she was a research poster

presentation finalist. In the coming year, she will finalize sever-al manuscripts (including her master’s thesis on statin use and left ventricular structural remodeling), serve as an RA for Ryan Hansen, write two more preliminary exams, and explore poten-tial dissertation topics in neurology and/or substance use.

Lucille Sun, PharmD, UW/Bayer Post-Doctoral Fellow 2016-2018 Lucille joins the Bayer US Health Econom-ics & Outcomes Research (HEOR) team for the second year of her fellowship with the University of Washington (UW) and Bayer. As a first-year, she completed her Master's coursework and thesis, a retrospective claims database analysis on the incidence of depressive and anxiety

disorders in commercially insured patients with non-Hodgkin lymphoma (NHL) in the US. She also developed a partition state survival model to assess the cost-utility of first-line treat-ments in follicular lymphoma. Prior to attending UW, she re-ceived her PharmD from the University of California at San Francisco (UCSF), where she led the student chapter of the Academy of Managed Care Pharmacy (AMCP). She previously interned at Genentech's HEOR department, conducting retro-spective database analyses in orphan diseases. She further took on a role in Genentech’s Global Pricing & Market Access group, developing materials to support affiliate negotiations with payers for launch of Cotellic in metastatic melanoma. Lu-cille looks forward to applying methods and concepts from PORPP to value evidence generation and health technology assessment, as well as building a diverse array of experienc-es at Bayer.

9

Certificate in Health Economics and Outcomes Research

SOP GRADUATE PROGRAM AWARD RECIPIENT

The UWSOP Graduate Student Leadership Award honors graduate stu-dents who have demonstrated outstanding leadership and service and have had a positive impact on the School of Pharmacy, UW, the Northwest com-munity, scientific and/or professional community. This year, the award goes to three students: Mark Bounthavong, Ryan Seguin, and Elijah Weber. Mark Bounthavong, PharmD, MPH, is a PhD student in the Pharma-ceutical Outcomes, Research and Policy Program (PORPP) in the UWSOP’s Department of Pharmacy. He recently completed service as President of the UW Student Chapter of the International Society for Phar-macoeconomics and Outcomes Research (ISPOR). His doctoral disserta-tion chair, Associate Professor Beth Devine, PhD, PharmD, MBA and Di-rector, Graduate Program, PORPP, writes, “Mark’s intellect, inquisitive na-ture, drive, genuine personal warmth, fundamental desire to help others and, of course, leadership skills are reasons that will make us all proud to have him as recipient of this award.” Dave Veenstra, PharmD, PhD, Profes-sor and Associate Director of PORPP writes, “As a PORPP student, Mark serves as a role model for other students.” Mark’s work with the National Academic Detailing Program in mental health illness demonstrates a strong commitment to caring for Veterans. Mark will receive his award at the Welcome Back Graduate Program Reception on October, 16th 2017.

Mark Bonthavong, PharmD, MPH, and PhD Candidate

10

The Certificate in Health Economics and Outcomes Re-

search program is entering its 6th year. Launched at the

start of the 2012-2013 academic year in conjunction with

the UW Professional and Continuing Education program,

this distance learning program is designed for profession-

als working in health care settings including payer organi-

zations, health insurance industry, government, the life

sciences, pharmaceutical and biomedical industries, and

for professionals working within Health Technology As-

sessment or reimbursement organizations. The program

offers one course per academic quarter; Fall quarter: Prin-

ciples of Health Economics, taught by Lou Garrison and

Anirban Basu; Winter quarter: Economic Evaluation,

taught by Dave Veenstra and Josh Carlson; Spring quar-

ter: Practice of HTA in a Global Environment, taught by

Sean Sullivan and Beth Devine. During the program, stu-

dents learn the key economic concepts and analytical

tools of human economic behavior, explore the current

state-of-the-art in the economic evaluation of health care

technologies, and are introduced to the principles and

methods of HTA practice. Students work in groups

throughout the program on a capstone project, which ap-

plies their learning to an assigned country. Student evalu-

ations have remained positive over the years. Many of the

students are international, a testament to the program’s

global reach. Applications have routinely been 60+ since

the beginning of the program. The 2017-2018 program is

on target to reach similar numbers. The program now has

an active LinkedIn alumni group. Courses are continually

being updated and revised to keep pace with changing

technologies and economies. Revenues from the Certifi-

cate in Health Economics and Outcomes Research pro-

gram support 1-2 PORPP teaching assistant positions

each year.

https://www.pce.uw.edu/certificates/

health-economics-and-outcomes-research

A BIG THANK YOU TO OUR DONORS

Pacific Northwest Evidence-based Practice Center (PNW EPC)

Beth Devine and John Gore are the Assistant Directors

and site principal investigators of the AHRQ-funded Pa-

cific Northwest Evidence-based Practice Center (PNW

EPC) who, along with Paul Kraegel, UW EPC Program

Manager, coordinate EPC projects across the three part-

ner institutions: Oregon Health & Science University, the

University of Washington CHASE Alliance, and Spec-

trum Research (Tacoma, WA). The UW joined the EPC

program in 2013, and, to date has participated in fifteen

projects ranging in scope from imaging for hepatocellular

cancer to pharmacologic and non-pharmacologic treat-

ments for schizophrenia. A current project that synthe-

sizes the existing literature on the use of telehealth mo-

dalities for acute and chronic consultation is also incor-

porating the use of decision modeling to estimate the

outcomes of specific telehealth interventions. Combining

evidence synthesis with decision modeling is a new un-

dertaking for AHRQ in their EPC V program and, with

modeling expertise from PORPP faculty member Ryan

Hansen, the PNW EPC was awarded the first of these

contracts. A pending application involves decision mod-

eling for lung cancer. PORPP faculty member, Josh

Roth, will lead. Numerous additional PORPP faculty

have led and participated in EPC projects. These include

Joseph Babigumira, Josh Carlson, Laurie Gold, Ryan

Hansen, Scott Ramsey, Sean Sullivan, and numerous

colleagues from the UW Schools of Medicine and Public

We extend our gratitude for your generous support to the PORPP program. Your contributions continue to expand opportunities, uphold academic excellence and

encourage our students and faculty to be pioneers in their fields.

Shelby & Steve Reed

Preeti Bajaj

Benevity

Josh Carlson

Julia Slejko

Julie & David Veenstra

Pan Foundation

Merck & Co., Inc. Amgen

Anirban Basu

Joshua Roth

Jennie Best Genentech, Inc.

Beth Devine

Christina & Jonathan Campbell

Meghann Galvin Novo Nordisk

Takeda Pharmaceuticals

AbbVie, Inc.

Bayer AG

Allergan Foundation

Pfizer Global Research & Development

Tom Hazlet Dana Hurley

11

Fran & Lou Garrison

Higashi Family

Bruce Wang

POST-DOCTORAL FELLOWS

Alice Ellyson, PhD Alice started as the Pfizer Postdoctor-al Fellow in August 2016 after receiv-ing a PhD in Economics from Florida State University. Since joining PORPP, she has expanded her work in physician decision-making including a collaboration with Jevay Grooms and Alberto Ortega, Assistant Profes-sor at Whitman College, on opioid prescribing and prescription drug monitoring programs. This supple-ments her existing work on medical malpractice and physician choices,

including a $35,000 grant awarded by the Gus. A Stavros Cen-ter and work with Justin Robertson entitled, "Can malpractice pressure compel a physician to relocate?" In addition, Alice has investigated issues in pharmaceutical pricing, including insulin price increases and oral chemotherapy parity law effects with Anirban Basu. In the summer of 2017, she spent time in New York City at Pfizer Inc. working with mentor Cristi-na Masseria on the economic burden of undiagnosed nonvalvu-lar atrial fibrillation.

Jevay Grooms, PhD Grooms’ research focuses broadly on factors which impede the effective-ness of various health policies as they relate to underrepresented communi-ties. Some of her current research focuses on domestic health policies and interventions geared toward indi-viduals who suffer from substance use disorders and behavioral health conditions as well as Medicaid Expan-sion. This body of research includes opioid prescribing behavior of physi-cians, the effectiveness of prescription

drug monitoring programs, the effect of a national opioid adviso-ry, and access to treatment facilities for mental and behavioral health. This spring she was named a fellow in the NSF funded Diversity Initiative for Tenure in Economics. She also spent part of the summer as a Visiting Assistant Professor in the American Economic Association Summer Program at Michigan State Uni-versity.

Melissa Rosen, PhD Melissa received her PhD in Social Policy from Brandeis University in 2016. In addition, she holds Master of Public Health and Master of Sci-ence in Nutrition degrees from Tufts University. Her research has focused on Medicare Part D insurance plan switching behavior and associated health and spending outcomes among individuals with chronic men-tal and physical illnesses. Additional research interests include psycho-tropic medication access and adher-ence, policies and programs that

affect Medicare-Medicaid dually eligible beneficiaries, and im-pacts of drug plan formularies and utilization controls on medi-cation utilization, cost and health-related outcomes. As part of

Liisa Laine, Afflilate Faculty, PhD Candidate Liisa T. Laine is a PhD candi-date in Economics at Jyväskylä University School of Business and Economics, Finland, and holds a master’s degree in Eco-nomics and a bachelor's degree in Mathematics. She will be re-ceiving her PhD in Economics in 2017. Before the Yrjö Jahnsson Foundation postdoctoral fellow-ship, Liisa was a visiting scholar

at the Economics departments in Columbia University (2015-2017) and Boston University (2012-2017). Liisa's research interests lie in industrial organization with a par-ticular focus on health care. In her PhD dissertation, she studied theoretical models of quality and price competi-tion between public and private providers and did empiri-cal research on the effects of obesity on long-term labor market outcomes. Liisa's current research concerns the effects of health information on drug monitoring programs and the effects of choice in public health care.

her fellowship, she worked on NIH funded research for Dr. Anirban Basu and Dr. Norma Coe including, their “Value of Information Methods for NHLBI Trials” and “Current and Future Costs of Alzheimer’s and Dementia Care” projects. Melissa Rosen has accepted a position as a Senior Health Economist at Fresenius Medical Care North America in Boston.

Marita Zimmermann, PhD Marita Zimmermann is working on a UW project team with the Institute for Clinical and Eco-nomic Review (ICER). She recently completed cost-effectiveness models in multi-ple sclerosis and atopic derma-titis. She presented both of these projects at ICER public meetings, which are using to communicate with stakeholders and inform policy and reim-bursements decisions. She is

currently working on a cost-effectiveness analysis of a gene therapy for blindness. In addition, Marita contin-ues to work on economic and other global health pro-jects, including the cost-effectiveness of a Japanese Encephalitis vaccine in the Philippines, and etiological costs of diarrhea disease.

12

2017 Garrison Prize in Health Policy & Economics

2017 PORPP GRADUATE STUDENTS AT ISPOR

Top (from left): Lucille Sun, Wei-Jhih Wang, Lauren Strand Bottom (from left): Mark Bounthavong, Dave Veenstra, Kangho Suh and Sheila Shapouri

The Louis Garrison Sr. and Marilyn Garrison Endowed Prize in Health Policy and Economics is intended to recognize an-nually an outstanding research paper in the area of health policy and economics. PORPP Professor Louis Garrison, Jr, and his wife, Fran established this fund in 2008 in fond memory of his parents Louis P. Garrison, Sr. and Marilyn J. Garrison, who were great believers in the value of education and science. Congratulations to Erik Landaas for his winning paper titled: “Expanding Evidence-Based Technology Assessment for Coverage in Washington State.” Erik received a $1,000 monetary award and plans on conducting further HTA studies to evaluate the value of HTA programs in hospitals, other states and regions in the US.

Erik Landaas and Beth Devine

Erik Landaas and Lou Garrison

13

RESEARCH HIGHLIGHTS

Ryan Hansen, Joseph Babigumira, and Beth Devine are participating in an AHRQ Evidence Based Practice Center project evaluating Telehealth Consultations be-tween medical providers. In partnership with our colleagues at OHSU, the team is performing a systematic review that was developed from an earlier evidence map

project and our PORPP group is also responsible for creating two decision analyses evaluating the use of this technology in the US Health Care System and also in-vestigating the impact of novel payment models. Ryan Hansen and colleagues from the Kaiser Perma-nente Washington Health Research Institute (formerly Group Health) recently completed a PCORI funded eval-uation (PI: Michael Von Korff) of opioid dose reduction efforts that occurred at Group Health in order to under-stand the impact of those dose reductions on overdose risk, medically attended injuries, and motor vehicle crashes. The team also surveyed current chronic opioid therapy patients in order to better understand their rela-tionships with their medical providers. Publications from this project will be entering the public domain throughout the summer and fall. Jenny Bacci, Peggy Odegard, Andy Stergachis, and Ryan Hansen have been working with community phar-macy partners at Bartell Drugs and QFC Pharmacies to evaluate strategies to increase adult vaccination rates for pneumonia, influenza, shingles, and whooping cough. This project, funded by the National Association of Chain Drug Stores, is implementing novel pharmacist-driven interventions to promote increased vaccinations and re-duce the risk of these important adult infections. Through the implementation project we are also testing new reim-bursement models and incentives that are aimed at fur-ther increasing rates and sharing risk for the patients who are not vaccinated with insurers.

Andy Stergachis was senior author of the largest meta-analysis of all observa-tional studies-to-date showing there was no difference in the risk of miscarriage, still births or major birth defects associat-ed with the use of artemisinins anytime during the first trimester, compared with quinine. The study, “First- trimester arte-

misinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies,” was published in PLoS Medicine and coordinated through the Malaria in Pregnancy Consortium, established in 2007 at the Liver-pool School of Tropical Medicine to improve the control and prevention of malaria in pregnancy. We analyzed data from five studies involving 30,618 pregnancies: four studies from Zambia, Tanzania, Rwanda, Kenya, Mozambique, Burkina Faso, and one large study from

the Thailand based Shoklo Malaria Research Unit. We found no increase in the risk of miscarriage, stillbirth, or major birth defects associated with the use of artemis-inins anytime during the first trimester compared with the use of quinine during the same gestational period. Lim-ited safety data on the use of artemisinins in human preg-nancies have historically prevented health authorities from recommending these therapies for malaria treatment in the first trimester, except in life-saving circumstances. It is possible that this study may result in a major change to recommended guidelines for the administration of arte-misinins in the first trimester of pregnancy.

Josh Carlson’s research over the last 10 years has sought to inform healthcare decision making using eco-nomic modeling, evidence synthesis, preference assessment, and health poli-cy evaluation. This work has spanned many diseases, topics, and methodolo-gies, but specific focus areas include precision medicine, cancer, and perfor-mance-based risk sharing arrange-ments. He has diverse formal training in

public health genetics, decision modeling, discrete choice experiments, comparative effectiveness, and outcomes research. Current projects include work with the Institute for Clinical and Economic Review (ICER), in which he leads a team in the development of economic models as part of ICER evaluations of new medical technologies. He is also working on two projects using value of information techniques to inform research prioritization activities with SWOG (UW PI)—a large cancer cooperative group, and the National Health Lung and Blood Institute (Co-investigator). He is a co-investigator on our PRIMER grant through the NIH common fund, leading aim two evaluating patient, provider, and payer preferences for precision medicine. Finally, he manages the performance-based risk sharing arrangements database and produce scholarly works and presentations on this evolving health policy topic.

In light of the current opioid epidemic in the U.S., Denise Boudreau’s current re-search portfolio has a major focus on opi-oid safety and treatment of opioid use dis-order. Currently, she is Co-Principal In-vestigator of a large FDA mandated post-marketing safety study of misuse, abuse, and addiction with extended release/long

acting opioids, and Co-investigator on a FDA mandated study to develop and validate diagnostic algorithms to measure abuse and addiction (http://www.fda.gov/Drugs/NewsEvents/ucm384489.htm). She is also leading a large, multisite, FDA funded study on opioid use during pregnancy and risk of birth defects and a co-investigator on a NIDA funded trial of buprenorphine to treat opioid

15

RESEARCH HIGHLIGHTS

use disorder. In 2017, they will also be launching a project at Kaiser Permanente Washington to better understand how to successfully taper patients off opioids or reduce their dosage.

Scott Ramsey and his team are performing prospective and retro-spective analyses aimed at improv-ing value in the use of drugs, devic-es, and interventions aimed at reduc-ing the human and economic burden of cancer. The Hutchinson Institute for Cancer Outcome Research which he directs is also developing novel approaches for multi-stakeholder engagement in research. He is cur-

rently directing a large, prospective randomized controlled trial evaluating approaches to improve colony stimulating factor prescribing for patients receiving myelosuppressive chemotherapy.

Aasthaa Bansal, in collaboration with Anirban Basu and Dave Veenstra, is using predictive model-ing and decision theory to develop methods for the optimal timing of treatment and biomarker testing in settings of long-term patient follow-up. This work is motivated by Aasthaa's research on treatment sequencing in chronic myeloid leu-kemia, which was funded by a re-search starter grant from the PhRMA

Foundation. Aasthaa is also working with PORPP affiliate faculty Lotte Steuten on methods for developing cost-effective biomarker combinations for disease diagnosis and prognosis. Finally, she is a co-investigator and lead statisti-cian on a PCORI-funded pragmatic trial in cancer, as well as studies on survival, costs and resource utilization in can-cer using large healthcare claims databases and EHR, where she is collaborating with PORPP affiliate faculty Scott Ramsey at the Hutchinson Institute for Cancer Out-comes Research.

Sean Sullivan, Julia Slejko, and Anirban Basu published a paper on the “Returns to scientific publications for pharmaceutical products in the United States” in Health Economics in August 2017. Five years in the making, this paper was part of the last Health Tech Fund project. This study looks at the effect of publications on revenue for 22 branded drugs in 3 markets – statins,

rheumatoid arthritis and asthma – using an ‘event-study’ approach combined with quarterly US sales data from 2003-2013. They hypothesize that publications should have an important impact on sales in markets with high generic

competition, and less in those without or with high branded competition. Using econometric methods that controls for un-observed drug-specific confounders, they find evidence sup-porting these hypotheses. For statins and asthma drugs, where there was some competition, clinical studies in high-impact journals increased sales in the next quarter by $8 million per publication. In rheumatoid arthritis, where competition is lim-ited, the effect on sales was mediated by the effect on volume. Studies published in lower impact journals seemed to have a negative influence. HEOR studies were only important in the market with high generic competition, increasing statin sales in

the next quarter following publication increased by $2.2 million on average. Our results indicate that investments by manufac-turer on clinical and HEOR need to be strategic and that such strategies should account for and also be complemented with public investments in such studies to achieve a more efficient production of clinical and HEOR information that can improve patient welfare.

Precision medicine, specifically phar-macogenomics, is an area of research focus for PORPP. This year, Beth Devine studied pharmacogenomic biomarkers from two perspectives. First, using data from the FDA’s Table of Pharmacogenomic Biomarkers and PharmGKB, she and her team charac-terized the strength of evidence in FDA labels for pharmacogenomic biomarker-guided medication use. Studying 137

drugs, involving 49 biomarkers, they found the strength of evi-dence for pharmacogenomic biomarker use is low, underscor-ing the need for additional research to achieve the promise of precision medicine. Assisting her were current UW-Bayer fel-low, Lauren Chin and PORPP alumni Will Canestaro, Kate Keyloun and Sarah Baradaran. Their work was nominated for the Marco Ramoni Distinguished Paper Award at the American Medical Informatics Association Joint Summits on Translational Science, San Francisco (March 2017). Second, using clinical data from the UW electronic health record, Beth’s team esti-

mated the frequency of pharmacogenomic-guided medication use in routine clinical practice, and found that use was ex-tremely low, especially for germline (versus somatic) bi-omarkers. Current PORPP PhD students Nathaniel Hendrix and Wei-Jhih Wang, and PORPP alumna Kate Keyloun joined Beth in this research, now published in Clinical Pharmacology and Therapeutics.

BE BOUNDLESS

16

The University of Washington School of Pharmacy

(UWSOP) and the Institute for Clinical and Economic Re-

view (ICER) formed a partnership in 2016. This collabora-

tion leverages UWSOP’s expertise in economic modeling of

pharmaceutical interventions to support ICER’s growing

body of work in new drug assessments. The UWSOP’s

Pharmaceutical Outcomes Research and Policy Program

(PORPP) research team develops cost-effectiveness mod-

els for soon-to-be or recently FDA approved drugs, leverag-

ing evidence synthesis work performed by ICER and pub-

licly-available data.

The UW team is comprised of faculty (Josh Carlson (PI),

David Veenstra, Anirban Basu, and Lotte Steuten), staff

scientists (Greg Guzauskas and Marita Zimmermann), and

graduate students (Elizabeth Brouwer and Nathaniel Hen-

drix). To date we have completed economic evaluations on

6 topics: multiple myeloma, non-small cell lung cancer

(NSCLC), plaque psoriasis, multiple sclerosis, atopic der-

matitis, and osteoporosis.1-6 We are currently working on

an evaluation of voretigene neparvovec, a gene therapy for

vision loss associated with biallelic RPE65-mediated retinal

disease.7

In addition to the work being presented at ICER public

meetings and published as part of ICER’s full topic reports,

our work has been disseminated at the 2017 ISPOR annual

meeting in Boston (5 abstracts) and via peer reviewed jour-

nals—1 in press (multiple myeloma) and 1 under review at

Annals of Internal Medicine (plaque psoriasis).8-13 A de-

tailed description of our findings is beyond the scope of this

summary, but overall we found that dupilimab in atopic der-

matitis, drugs used in plaque psoriasis (adalimumab,

etanercept, infliximab, ustekinumab, brodalumab, ixeki-

zumab, secukinumab and apremilast), tyrosin kinase inhibi-

tors (erlotinib, gefitinib, and afatinib) in NSCLC, and

alemtuzumab in multiple sclerosis provided intermediate to

high value for money according to ICER’s thresholds,

whereas the other drugs for these conditions and the drugs

for the other conditions were generally considered to pro-

vide low value for money. Of note, daratumumab in multi-

ple myeloma was subsequently found to provide good val-

ue for money according to ICER’s thresholds in a follow-on

peer reviewed publication that included data that was not

available during the initial review.8

Our interactions with key stakeholders, primarily patient

groups and manufacturers, have been extremely helpful to

the process. One interaction that warrants mention was

that with Sanofi/Regeneron on the evaluation of dupilimab

in atopic dermatitis, in which the manufacturer was fully

engaged in the process and worked iteratively with the

ICER team and health insurers more broadly to establish a

value based price for their new product.

Our overall experience developing economic evaluations as

part of ICER’s topic reviews has been very positive. We

feel that our work in collaboration with ICER, along with that

of the other modeling teams from the University of Colora-

do, led by PORPP alum Jon Campbell, and the recently

added group from the University of Illinois Chicago led by

Daniel Touchette, has raised the profile of health econom-

ics and outcomes research in United States and contribut-

ed valuable evidence to support healthcare decision mak-

ing for a variety of healthcare stakeholders. We look for-

ward to continued collaboration with ICER and interaction

with stakeholders to improve the process of assessing the

value of pharmaceuticals in the U.S.

UW PORPP AND ICER COLLABORATION

17

Staff scientists Greg Guzauskas (left), Marita Zimmermann (right)

Students

Blythe Adamson

United States Delegate to the 6th Lindau Nobel Laureate Meeting on Economics (August 2017)

ISPOR Outstanding Service Award (May 2017)

Third Place in Global Innovation eXchange (GIX) Competi-tion Finals in Beijing, China, (Nov 2016)

Mark Bounthavong

Graduate Student Leadership Award, University of Wash-ington, School of Pharmacy

Rubenstein Scholarship Fund, University of Washington, School of Pharmacy

Alumni Achievement Award, Western University of Health Sciences, College of Pharmacy

Lizzy Brouwer

Rubenstein Scholarship Fund, University of Washington, School of Pharmacy

Horacio Duarte

Diagnostics Abstract Award at the IDWeek 2016 Confer-ence (Infectious Diseases Society of America) in New Orle-ans, LA

Young Investigator Award at 2017 Conference on Retrovi-ruses and Opportunistic Infections

Laura Hart

2016-2017 UW Retirement Association Graduate Student Fellowship in Aging

ACCP Research Institute Futures Grant to support thesis research

Erik Landaas

PORPP endowed prize in Health Policy and Economics

AHRQ T-32 pre-doctoral fellowship trainee and Eli Lilly awardee

Meng Li

Rubenstein Scholarship Fund, University of Washington, School of Pharmacy

Solomon Lubinga

Scholarship Recipient, Reducing Barriers for the Ambitious Fund

Rubenstein Scholarship Fund, University of Washington, School of Pharmacy

Sheila Shapouri

Washington State Student Pharmacist of the Year (Awarded by Washington State Pharmacy Association; Annual Meeting-November 2015)

Lauren Strand

ISPOR 22nd Annual International Meeting Research Presentation Award Finalist

Elisabeth Vodicka

PORPP Endowed Prize in Health Policy and Economics (Co-Recipient)

Scholarship Recipient, Human Rights to Family Planning

Conference, Seattle, WA

Scholarship Recipient, Reducing Barriers for the Ambitious Fund

Rubenstein Scholarship Fund, University of Washington, School of Pharmacy

Wei-Jhih Wang

Rubenstein Scholarship Fund, University of Washington, School of Pharmacy

Faculty & Post-Docs

Brian Bresnahan

June 2017, recipient of a 2017 Radiologic Society of North America (RSNA) Honored Educator Award.

Beth Devine

2017-2019: Member by competitive appointment, Academy Health Methods Council, 2017-2020.

2017:Manuscript nominated for the Marco Ramoni Distin-guished Paper Award, American Medical Informatics Associa-tion (AMIA) Joint Summits on Translational Science. The Marco Ramoni award recognizes the paper that best exempli-fies the spirit and scholarship of Marco Ramoni in applying informatics methods to the elucidation of basic molecular biol-ogy processes that are relevant to the conquest of human disease. Chin, Devine (co-primary authors), et al. Character-izing the Strength of Evidence in FDA Labels for Phar-macogenomic Biomarker-Guided Medication Use. AMIA Jt Summits Transl Sci Proc. 2017 Jul

2017: Guest editor, Concordium 2016 Special Issue Papers in: eGEMs; Generating Evidence & Methods to improve pa-tient outcomes. Academy Health. Devine B. Data and Knowledge Transforming Health. eGEMs. 2017;5(Issue 2).

Ryan Hansen

2017 Award of Excellence in Healthcare Quality, Founda-tion for Healthcare Quality/Washington Patient Safety Coali-tion: Kelley-Ross Pharmacy Group

2016 Pinnacle Award, American Pharmacists Association Foundation: Kelley-Ross Pharmacy Group

Zachary Marcum

2017 ACC/AGS/NIA Pharmacotherapy in Older Adults with CVD Workshop Travel Award Winner

HONORS AND AWARDS

18

GIFTS

STUDENT HIGHLIGHT

PORPP Student research identifies costs for health plans that exclude contraception

By Sarah C.B. Guthrie

At companies whose health insurance plans exclude contraception coverage, female employees experi-enced 33 more unintended pregnancies per 1,000 women, and more unintended births and terminations. Such plans might also result in higher overall costs for employers. Those were the primary findings of a study led by the University of Washington School of Pharmacy and Princeton University, recently published in the journal Contraception. “The women who were most affected were ages 18 to 24 or over 40 years old,” said Will Canestaro, a UW graduate student and one of the study’s two lead authors. “Essentially, women at the start and end of their reproductive years were most sensitive to the costs for paying out of pocket for birth control.”

It’s well established that access to birth control lowers unintended pregnancies and terminations, and is cost-effective at the societal level. Under the Affordable Care Act (ACA), employers are required to cover birth control, but in recent years several employers have gone to court to opt out of the requirement. Canestaro and colleague Elisabeth Vodicka were curious about the effects that private health insurers’ birth-control coverage had on plan costs and reproductive-health de-cisions of women on those plans.

The students reached out to Don Downing, a UW pharmacy profes-sor, and health economist James Trussell, professor emeritus of eco-nomics and public affairs at Princeton University. He specializes in reproductive health and demographic methodology. The team used a model to extrapolate outcomes for a large, national-ly representative sample and found a statistically significant differ-ence in unintended pregnancy and terminations. “Employers may be opting out of providing birth control, but this study suggests that offering no coverage may result in an increase in unintended pregnancies, terminations, and increased costs for the employer-paid plans,” Vodicka said. Employers whose insurance plans lack birth control coverage may face difficulty recruiting and retaining women in the age groups most affected in the study, Canestaro added. The model created by the team creates opportunity for further study, including the return on investment for employers choosing to opt in or out of plan coverage for birth control; the impact that public-plan coverage, such as Medicaid, may have on unintended pregnancies; and the overall impact to population health in America by modeling how many women are affected by these plans’ benefit decisions. “Ultimately, we want to aid employers in making informed decisions,” Vodicka said.

To see the original op-ed published in the Seattle Times, go to: bit.ly/STop-ed

24

BLYTHE ADAMSON Adamson B, Carlson J, Kublin J, Garrison L. The Potential Cost-Effectiveness of Pre-exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines 2017, 5(2), 13; doi:10.3390/vaccines5020013 Adamson B, Dimitrov D, Devine D, Barnabas R. The Poten-tial Cost-Effectiveness of HIV Vaccines: A Systematic Review. Pharmacoeconom Open. 2017 Mar;1(1):1-12. doi: 10.1007/s41669-016-0009-9. Epub 2017 Jan 30. Lutz B. Jain R. Adamson B. “Connected System for Information-Enhanced Test Results,” U.S. Provisional Patent Application No. 62/422,506, filed November 15, 2016. MARK BOUNTHAVONG Oliva EM, Christopher ML, Wells D, Bounthavong M, Harvey M, Himstreet J, Emmendorfer T, Valentino M, Franchi M, Good-man F, Trafton JA; Veterans Health Administration Opioid Overdose Education and Naloxone Distribution National Sup-port and Development Workgroup. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program. J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S168-S179. Bounthavong M, Harvey MA, Wells DL, Popish SJ, Him-street J, Oliva EM, Kay CL, Lau MK, Randeria-Noor PP, Phillips AG, Christopher ML. Trends in naloxone prescriptions pre-scribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: A preliminary analysis. J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S68-S72. Bounthavong M, Pruitt LD, Smolenski DJ, Gahm GA, Bansal A, Hansen RN. Economic evaluation of home-based telebehavioural health care compared to in-person treatment delivery for depression. J Telemed Telecare. 2016 Nov 12. pii: 1357633X16678147. [Epub ahead of print] ELIZABETH BROUWER Salti N, Brouwer E, Verguet S. The health, financial and distri-butional consequences of increases in the tobacco excise tax among smokers in Lebanon. Social Science & Medicine. 2016 Dec 31;170:161-9.

SHUXIAN CHEN

Carlson JJ, Chen S, Garrison LP, Jr. Performance-Based Risk-Sharing Arrangements: An Updated International Review. Phar-

macoeconomics. 2017

POSTER: Chen S, Carlson JJ. Evaluating the efficiency of cov-erage with evidence development implementation. ISPOR 22nd Annual International Meeting May 20-24. Boston, MA, USA

LAURENCHIN

Yu JS, Chin L, Oh J, Farias J. Systematic Review of Perfor-mance-Based Risk-Sharing Agreements for Pharmaceutical Products in the United States. JMCP. (accepted 4/13/2017 to

JMCP) **Chin L, **Devine B, Baradaran S, Keyloun K, Canes-taro WJ, Pham J. Characterizing the strength of evidence in FDA Labels for pharmacogenomic biomarker-guided medica-

tion use. AMIA Jt Summits Transl Sci Proc. (**co-primary au-thors; accepted 12/8/2016 to AMIA Jt Summits Transl Sci Proc)

SAMANTHA CLARK Ozawa S, Portnoy A, Getaneh H, Clark S, Knoll M, Bishai D,

Yang H, Patwardhan P. Modeling the Economic Burden of Adult Vaccine Preventable Diseases (VPDs) in the United States. Health Affairs. November 2016; 35(11):2124-2132

Verma R, Clark S, Leider J, and Bishai D. Impact of state public

STUDENT PUBLICATIONS

health spending on incidence of mumps, pertussis, and rubella in the United States from 1980-2009. Health Services Re-

search. February 2017; 52(1):176–190. Ozawa S, Clark S, Portnoy A, Grewal S, Stack M, Sinha A, Mirelman A, Franklin H, Friberg I, Tam Y, Walker N, Clark A,

Ferrari M, Suraratdecha C, Sweet S, Goldie S, Garskie T, Li M, Hansen P, Johnson H, Walker D. Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001–

2020. Bulletin of the World Health Organization. June 2017. Advance online publication.

SHALAK GUNJAL Cintron, D., Lipford, M., Larrea-Mantilla, L., Spencer-Bonilla, G., Lloyd, R., Gionfriddo, M. R., Gunjal SS … Murad, M. H. (2017). Efficacy of menopausal hormone therapy on sleep quality: sys-tematic review and meta-analysis. Endocrine, 55(3), 702–711.

ERIK LANDAAS

Landaas, E., Franklin, G., Thompson, J., Lessler, D., Morse, J., Mootz, R., . . . Sullivan, S. (2016). EXPANDING EVIDENCE-BASED TECHNOLOGY ASSESSMENT FOR COVERAGE IN WASHINGTON STATE. International Journal of Technology Assessment in Health Care, 32(3), 140-146. doi:10.1017/S0266462316000192

MENG LI

Yeung K, Li M, Carlson JJ. VALUE - Using Performance-Based Risk Sharing Arrangements to Address Uncertainty in Indica-tion-Based Pricing. Journal of Managed Care Pharmacy. In Press. Li M, Nyabigambo A, Navvuga P, Nuwamanya E, Nuwasi-ima A, Kaganda P, Asiimwe FT, Vodicka E, Mugisha NM, Mukose A, Kwesiga DK, Lubinga SJ, Garrison LP, Babigumira, JB. Acceptability and Performance of Cervical Cancer Screen-ing Using Visual Inspection With Acetic Acid Among Women Attending A Childhood Immunization Clinic in Uganda. Papillo-mavirus Research. 4(2017) 17-21 Babigumira J, Li M, Boudreau D, Best J, Garrison L. Estimating the Cost of Illness of Giant Cell Arteritis. Rheumatology and Therapy. Rheumatol Ther (2017) 4: 111. SOLOMON LUBINGA Katusiime B, Semakula D, Lubinga SJ. Adverse drug reaction reporting among health care workers at Mulago National Refer-ral and Teaching hospital in Uganda. Afr Health Sci. 2015;15(4):1308-17 Lubinga SJ, Atukunda EC, Wasswa-Ssalongo G, Babigumira JB. Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Ugan-da. PLoS One. 2015;10(11):e0142550 Watkins D, Lubinga SJ, Mayosi B, Babigumira JB. A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African Nations. PLoS NTDs. In Press MICHAEL SERBIN Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clini-cal Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. JMCP. Pending publication (August 2016)

19

SHEILA SHAPOURI POSTER PUBLICATION Shapouri S, Devine EB. Cost-Utility Analysis of Outpatient Dalbavancin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) versus Inpatient Vancomycin Followed by Oral Linezolid. ISPOR 22nd Annual International Meet-ing; May 20-14, 2017; Boston, MA KANGHO SUH Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ. Paying for cures: how can we afford it? Managed care pharmacy stakeholders’ perceptions of policy options to address affordability of prescription drugs. Journal of Man-aged Care & Specialty Pharmacy (accepted and expected print October 2017). Suh K, Basu A, Yeung K, Bansal A, Garrison LP, Carson JJ. Concept analysis on cures for illnesses with high dis-ease burden. Abstract PHP297, Value in Health 20 (2017), A67-8. LAUREN STRAND Redonna Chandler, Mike Gordon, Bridget Kruszka, Lauren Strand, Frederick Altice, Curt Beckwith, … Heidi Crane. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Pre-vention, and Policy, 2017: 12(1), 24. https://doi.org/10.1186/s13011-017-0107-4 Lauren Strand, Alain Bertoni, David Bluemke, Joao Li-ma, Bruce Psaty, Susan Heckbert, Joseph Delaney, Robyn McClelland. The use of propensity score matching to esti-mate the association between new statin use and left ven-tricular structure: in the Multi-Ethnic Study of Atherosclero-sis (MESA). Accepted to the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Manage-ment, August 2017, Montreal Canada. Maria Esther Perez Trejo*, Lauren Strand*, Robin Nance, Bridget Kruszka, Frederick Altice, Curt G Beckwith, Redon-na Chandler, Charles M Cleland, Heidi M Crane, Chinazo Cunningham, William Cunningham, Joseph A Delaney, Daniel J Feaster, Shoshana Kahana, Irene Kuo, Lisa Metsch, Elise Riley, Wendee Wechsberg, Shoshana Ka-hana, Sandra Springer. The role of gender as an effect measure modifier in the Seek, Test, Treat, Retain (STTR) HIV Consortium: evaluating the relationship between an-tiretroviral adherence and poly-substance use. Accepted to the 33rd International Conference on Pharmacoepidemiolo-gy and Therapeutic Risk Management, August 2017, Mon-treal Canada. * Co-first authors. Lauren Strand, Marita Zimmermann, Josh Carlson, Ryan Hansen. Cost-utility of early versus delayed treatment with interferon beta-1b in clinically isolated syndrome from a United States payer perspective. Accepted to the INterna-tionap Society for Pharmacoeconomics and Outcomes Re-search Annual Conference in May 2017, Boston MA. ELISABETH VODICKA Vodicka E, Babigumira JB, Mann M, Kosgei RJ, Lee F, Mugo N, Okech T, Sakr S, Garrison LP, Chung MH. Costs of Cervical Cancer Screening Methods Integrated into HIV Care in Nairobi, Kenya. 2017. Int J Gynecol Obstet. 136:220-228. doi:10.1002/ijgo.12025. Saldarriaga E, Vodicka E, La Rosa S, Valderrama M, Gar-cia PJ. Point of Care Testing for Anemia, Diabetes, and Hypertension: A Pharmacy-Based Model in Lima, Peru. Ann Global Health. 2017;83(2):394-404. http://dx.doi.org/10.1016/j.aogh.2017.03.514. “Want to Prevent Abortions? Provide Low-Cost Contracep-

PUBLICATIONS

tive Coverage.” Will Canestaro, Don Downing, and Elisabeth Vodicka. Seattle Times. Opinion. Print ver-sion published on January 29,2017. Published online on January 27, 2017 at: http://www.seattletimes.com/opinion/want-to-prevent-abortions-provide-low-cost-contraceptive-coverage/ SOUVIK BANERJEE Banerjee S, Chatterji P, Lahiri K. Effects of Psychiatric Disorders on Labor Market Outcomes: A Latent Variable Approach Using Multiple Clinical Indicators. Health Eco-nomics, 2015, doi: 10.1002/hec.3286 MARITA ZIMMERMANN Dupilumab and Crisaborole for Atopic Dermatitis: Effec-tiveness and Value. Institute for Clinical and Econom-ic Review. May 12, 2017. Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value. Institute for Clinical and Economic Review. March 6, 2017. Zimmermann MR, Vodicka E, Babigumira JB, Okech T, Mugo N, Sakr S, Garrison LP, Chung MH. Cost-efectiveness of cervical cancer screening and preventa-tive cryotherapy at an HIV treatment clinic in Ken-ya. Cost Ef Resour Alloc (2017) 15:13 Duintjer Tebbens, R.J., Zimmermann, M., Pallansch, M.A. et al. Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environ-mental Surveillance Sys-tems. Food Environ Virol (2017). doi:10.1007/s12560-017-9314-

FACULTY JOSEPH BABIGUMIRA Babigumira JB, Lubinga SJ, Castro E, Custer B: Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma. Blood transfusion = Trasfusione del sangue 2016:1-9. Babigumira JB, Li M, Boudreau DM, Best JH, Garrison LP, Jr. Estimating the Cost of Illness of Giant Cell Arteritis in the United States. Rheumatology and therapy. 2017. Epub 2017/01/14. doi: 10.1007/s40744-017-0052-8. PubMed PMID: 28084585. Vodicka EL, Babigumira JB, Mann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Garrison LP, Jr., Chung MH: Costs of integrating cervical cancer screening at an HIV clinic in Kenya.

Int J Gynaecol Obstet 2017, 136:220-228. AASTHAA BANSAL Bansal A, Sullivan SD, Lyman G, Hershman D, Barlow WE, McCune J, Ramsey SD (2017). A Stakeholder-Informed Ran-domized, Controlled Comparative Effectiveness Study of an Or-der Prescribing Intervention to Improve Colony Stimulating Factor use for Cancer Patients Receiving Myelosuppressive Chemother-apy, (SWOG S1415CD): The TrACER Study. Journal of Compar-ative Effectiveness Research, doi: 10.2217/cer-2017-0005. [Epub ahead of print] . Bansal A, Radich JP (2016). Is cure for CML possible in the TKI era? Current Opinion in Hematology, 23(2): 115-120. Othus M, Bansal A, Koepl L, Wagner S, Ramsey S (2017). Ac-counting for cured patients in cost-effectiveness analysis. Value in Health. 20(4): 705‐709.

ANIRBAN BASU Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and

20

FACULTY PUBLICATIONS

Reporting of Cost-Effectiveness Analyses in Health and Medicine: The Second Panel on Cost-Effectiveness in Health and Medicine. Journal of the American Medical Association 2016; 316(10): 1093-1103. Basu A, Sullivan SD. Towards a hedonic value framework in health care. Value in Health 2017; 20: 261-265. Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a Value-Based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Medical Care 2017; 55(2): 191-198.

DENISE BOUDREAU Boudreau DM, Yu O, Balasubramanian A, Wirtz H, Grauer A, Crittenden DB, Scholes D. A Survey of Adult Awareness and Rea-sons for Lack of Post-Fracture Osteoporotic Care. J Am Geriatr Soc. 2017 Apr 19. [Epub ahead of print]. Wirtz HS, Calip GS, Buist DSM, Gralow JR, Barlow WE, Gray S, Boudreau DM*. Evidence for detection bias in breast cancer pharmacoepidemology studies. Am J Epidemiol. 2017;185:661-672. Calip GS, Elmore JG, Boudreau DM. Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors. Breast Cancer Res Treat. 2017;161:161-172

BRIAN BRESNAHAN Hippe, DS, Lehnert, BE, Slade, I, Dellit, TH, Hough, CL, Schreuder, AB, Cohen, WA, Miklusis, J, Pergamit, R, Bresnahan, BW, Reducing utilization of portable chest radiographs in the intensive care unit: a quality improvement initiative, JACR, June 2017, in print.

JOSH CARLSON Carlson JJ, Chen S, Garrison LP, Jr. Performance-Based Risk-Sharing Arrangements: An Updated International Review. Phar-macoeconomics. 2017. Adamson BJS, Carlson JJ, Kublin JG, Garrison LP. The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines (Basel). 2017;5(2). Yu JS, Hansen RN, Valderrama A, Carlson JJ. Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57(11):2636-2643.

BETH DEVINE Mathias PC, Hendrix N, Wang WJ, Keyloun KR, Khelifi M, Tarczy-Hornoch P, Devine B. Characterizing pharmacogenomic-guided medication use with a clinical data repository. Clin Pharmacol Ther. 2017 Jan 10. doi: 10.1002/cpt.611. [Epub ahead of print] Chin L, Devine B, (co-primary authors) Baradaran S, Keyloun K, Canestaro WJ, Pham J. Characterizing the strength of evidence in FDA Labels for pharmacogenomic biomarker-guided medication use. AMIA Jt Summits Transl Sci Proc. 2017 Jul Agapova M, Bresnahan B, Linnau KF, Garrison LP, Higashi M, Kess-ler L, Devine EB. Using the Analytic Hierarchy Process for Prioritiz-ing Imaging Tests in Diagnosis of Suspected Appendicitis Academic Radiology. Acad Radiol. 2017 May;24(5):530-537. doi: 10.1016/j.acra.2017.01.001. Epub 2017 Mar 28.

LOU GARRISON Garrison LP, Kamal-Bahl, S, Towse, A. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in Health 20 (2017) Towse A, Garrison L. Value Assessment in Precision Cancer Medi-cine, Journal of Cancer Policy 11 (2017) 48–53 3. Garrison LP Jr, Zimmermann MR, Young CH, Crittendon J, Généreux P. Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. Cardiovasc Revasc Med. 2016 Dec 15.

RYAN HANSEN Von Korff MR, Walker RL, Saunders K, Shortreed SM, Thakral M, Parchman M, Hansen RN, Ludman E, Sherman K, Dublin S. Preva-lence of prescription opioid use disorder among chronic opioid thera-py patients after health plan opioid dose and risk reduction initiatives. International Journal of Drug Policy 2017. In Press. Hansen RN, Pham AT, Lovelace B, Balaban S, Wan GJ. Compar-ative Analysis of Inpatient Costs for Obstetrics and Gynecology Sur-gery Patients Treated with IV Acetaminophen and IV Opioids versus IV Opioid Monotherapy for Postoperative Pain. Annals of Pharma-cotherapy 2017. In Press.

Dick AAS, Hansen RN, Montenovo MI, Healey PJ, Smith JM. Body Mass Index as a Predictor of Outcomes Among Pediatric Kidney Transplant Recipient. Pediatric Transplantation 2017. In Press.

ZACHARY MARCUM Marcum ZA, Hanlon JT, Murray MD. Improving medication adherence and health outcomes in older adults: a narrative review of evidence from randomized controlled trials. Drugs Aging 2017;34:191-201. Hanlon JT, Perera S, Newman AB, Thorpe J, Donohue J, Si-monsick EM, Shorr RI, Bauer DC, Marcum ZA. Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults. J Clin Pharm Ther 2017;42:228-33. Marcum ZA, Gellad WF. Improving medication adherence: keep your eyes on the prize. J Gen Intern Med 2017;32:236-7.

JOSH ROTH Hart R, Veenstra DL, Boudreau DM, Roth JA. The Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. Am J Med. 2016 Sep 1. pii: S0002-9343(16)30860-9. PubMed PMID: 27593608. Carter-Harris L, Brandzel S, Wernli KJ, Roth JA, Buist DS. A quali-tative study exploring why individuals opt out of lung cancer screening. Fam Pract. 2017 Jan 24. pii: cmw146. [Epub ahead of print] PubMed PMID: 28122849. Roth JA, Goulart BHL, Ravelo A, Kolkey H, Ramsey SD. Sur-vival Gains from First‐Line Systemic Therapy in Metastatic Non‐Small Cell Lung Cancer in the U.S., 1990–2015: Progress and Opportunities. The Oncologist. 2017 Feb 27. PMID: 28242792.

SCOTT RAMSEY Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carl-son JJ. Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Deci-sions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Med Decis Making. 2016 Jul;36(5):641-51. doi: 10.1177/0272989X16636847. Epub 2016 Mar 24. PMID: 27012232 Mandelblatt JS, Ramsey SD, Lieu TA, Phelps CE. Evaluating Frameworks That Provide Value Measures for Health Care Inter-ventions. Value Health. 2017 Feb;20(2):185-192. doi: 10.1016/j.jval.2016.11.013. PMID: 28237193 Bansal A, Sullivan SD, Hershman DL, Lyman GH, Barlow WE, McCune JS, Ramsey SD. A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. J Comp Eff Res. 2017 Jul 7. [Epub ahead of print]

ANDY STERGACHIS Dellicour S, Sevene E, McGready R, Tinto H, Mosha D, Mayando C, Rulisa S, Desai M, Ouma P, Oneko M, Vala A, Ruperez M, Macete E, Menendez C, Nakanabo-Diallo S, Kazienga A, Valea I, Calip G, Augusto O, Genton B, Njunju EM, Moore KA, d'Ales-sandro U, Nosten F, ter Kuile F; Stergachis A. First trimester arte-misinin derivatives and quinine treatments and their association with adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. PLOS Medicine. 2017 May 2;14(5):e1002290.

Jenny AM, Li M, Ashbourne E, Aldrink M, Funk C, Stergachis A. Assessment of the scope and evaluation of medical donation pro-grams. Globalization and Health. 2016 Nov 4;12(1):69.

Mugwanya KK, Celum CL, John-Stewart GC, Mugo N, Katabira E, Bulya N, Ngure N, Stergachis A, Baeten J. Infant exposure to tenofovir and emtricitabine through breast milk when used as pre-exposure prophylaxis by HIV-uninfected lactating women. PLoS Med. 2016 Sep 27;13(9):e1002132.

21

SEAN SULLIVAN

Mathai SC, Minai O, Sullivan SD, Lerner D, Levine D. Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment. Respir Med 2017 Jan;122 Suppl 1:S23-S27

Bansal A, Sullivan SD, Lyman G, Hershman D, Barlow WE, McCu-ne J, Ramsey SD. A Stakeholder-Informed Randomized, Con-trolled Comparative Effectiveness Study of an Order Prescribing Intervention to Improve Colony Stimulating Factor use for Cancer Patients Receiving Myelosuppressive Chemotherapy, (SWOG S1415CD): The TrACER Study. Journal of Comparative Effective-ness Research 2017 (Jul) e-pub ahead of press.

Canestaro WJ, Hendrix N, Bansal A, Sullivan SD, Devine EB, Carlson JJ. Predictors of Publication for Biomedical Research: A Systematic Review and Meta-Analysis. J Clin Epi in press, 2017

DAVID VEENSTRA

Dhanda DS, Guzauskas GF, Carlson JJ, Basu A, Veenstra DL. Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy. Clin Pharmacol Ther. 2017 Feb 10. PMID: 28187492 Guzauskas GF, Chen E, Lalla D, Yu E, Tayama D, Veenstra DL. What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients? Int J Stroke. 2017 Feb;12(2):137-144. PMID: 28134053 Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. J Manag Care Spec Pharm. 2016 Aug;22(8):939-47. PMID: 27459657

DAVENE WRIGHT

Wright DR, Lozano P, Dawson-Hahn EE, Christakis DA, Haaland WL, Basu A. “Parental optimism about childhood obesity-related disease risks.” International Journal of Obesity. May 2017. doi:10.1038/ijo.2017.103 Wright DR, Lozano P, Dawson-Hahn EE, Christakis DA, Haaland WL, Basu A. “Parental Predictions and Perceptions Regarding Long-Term Childhood Obesity-Related Health Risks.” Academic Pediatrics. July 2016; 16: 475-481. PMID: 26875508. Wright DR, Haaland WL, Ludman E, McCauley E, Lindenbaum J, Richardson LP. “The costs and cost-effectiveness of collabora-tive care for adolescents with depression in primary care settings.” JAMA Pediatrics. November 2016; 170(11): 1048-1054. PMID: 26875508.

FACULTY PUBLICATIONS

22

JOSPEH BABIGUMIRA Gap in polymerase chain reaction (PCR) testing for chronic mye-loid leukemia in low-and middle-income countries. Max Foundation Framework for return on investment in pharmaceutical quality as-surance in middle-income countries. U.S. Pharmacopeial Conven-tion

AASTHAA BANSAL PI Comparative effectiveness of molecular response guided sequential treatment strategies in chronic myeloid leukemia Sponsor: PhRMA Foundation 2015-2017 Co-I (PIs: Sullivan, Ramsey) A Pragmatic Trial to Improve Col-ony Stimulating Factor Use in Cancer Sponsor: PCORI 2015-2019 Co-I (PI: Odegard) Implementing Value-Based Collaborations to Improve Immunizations Sponsor: National Association of Chain Drug Stores 2016-2017

ANIRBAN BASU Co-PI, (PI Coleman, Kaiser Permanente) NHLBI R01, Effective-ness of Gastric Sleeve vs. Gastric Bypass for Cardiovascular Dis-ease 2016-2019

DENISE BOUDREAU PI, The risks of opioid misuse, abuse and addiction among patients treated with extended-release/long acting (ER/LA) opioids for the treatment of chronic pain, Campbell Alliance, Ltd. 2015-2020. Co-Investigator/Task Order Lead, Evaluation of the Risk of Neural Tube Defects Among Live Births Exposed to Maternal Pre-scription Opioids During Early Pregnancy. FDA, 2016-2019. Co-Investigator, Primary Care Opioid Use Disorders Treat-ment Trial (PROUD) Coordinating Center, National Institute on Drug Abuse, 2017-2020.

JOSH CARLSON PI ICER Economic Modeling ; ICER, 1/2016-12/2017 Co-Investigator (Basu PI) Value of Information Methods for NHLBI Trials; NHLBI, 2015-2019 Co-Investigator (Veenstra PI), Personalized Medicine Econom-ics Research (PriMER) NIH/NIAAA, 2013-2018

BETH DEVINE PI, UW-Allergan Post-Doctoral Fellowship, Allergan Pharmaceuticals, 2012- Site PI, Pacific Northwest Evidence-based Practice Center (EPC) V, AHRQ, 2015-2019: 1) Medication Assisted Treatment (2016); 2) Treatment for Adults with Schizophrenia (2016-2017); 3) US Preventative Services Task Force (2016-2019) – a) BRCA-Related Cancer Risk Assessment/Genetic Testing; b) Breast Can-cer – Medications for Risk Reduction Co-I, (PI: Thompson) Patient-Centered Research for Stand-ards of Outcomes in Diagnostic Tests, PCORI Methods, 2015-2018

LOUIS GARRISON, JR. Principal Mentor, UW-Pfizer Post-Doctoral Fellowship, 2016-2018. PI, Estimating the Burden of Illness in Giant Cell Arteritis, Genentech, 2014-2016 Co-Inv. (PI-Chung) University of Nairobi HIV Capacity Building Fellowship. USAID, 2014-2018

RYAN HANSEN Mallinckrodt Pharmaceuticals: Estimating the Economic Impact of H.P. Acthar Gel in Infantile Spasms; Role: Principal Investigator AHRQ EPC-V: Telehealth for Acute and Chronic Consultation – Totten: PI; Role: Co-Investigator Cystic Fibrosis Foundation: Cost Effectiveness Analysis and Com-parative Effectiveness Research of STOP2; Kessler: PI; Role: Co-Investigator

ZACHARY MARCUM K12HS022982 UW K12 in Patient-Centered Outcomes Research (Sullivan PI) – AHRQ. Role: Scholar PI, Elmer M. Plein Endowed Research Fund American College of Clinical Pharmacy Research Institute Futures Grant Program, Mentor to Laura Hart

SCOTT RAMSEY Ramsey Sub-PI (Main PI Charles Blanke, OSHU) Ancillary Study to Evaluate Patient and Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in the SWOG 1400 (S1400) Clinical Trial. Project Dates 8/2016-2/2018

LOTTE STEUTEN Co-PI (PI-Hsu); Statistical Methods for Genetic Epidemiologic Studies; NIH/NCI, 2015-2019 Co-I (PI: Feng/Thornquist/Pepe), The Early Detection Re-search Network: Data Management and Coordinating Center; NIH/NCI 2000-2021

ANDY STERGACHIS PI Evaluating the Impact of Medical Donation Programs – Phase II. Partnership for Quality Medical Donations (PQMD). A Framework for Risk-Based Pharmaceutical Quality Assurance in LMICs. Babigumira (PI). United States Pharmacopeia.

SEAN SULLIVAN PI, CHASE K12 Training, 2014-2019, AHRQ

Co-Inv. (PI Linda Teri) From Evidence-Base to Practice: Imple-menting RDAD in AAA Community-Based Services. (National Institute of Aging) PI, K-12 Mentored Career Development Program in Patient-Centered Outcomes Research (AHRQ) July 2012 to June 2014. Co-Director, Pacific Northwest Evidence-Based Practice Center (AHRQ) August 2012 to July 2017 Co-Investigator, (PI-Ramsey) Pragmatic Trial of Pharmacist-based Guideline Use of CSF; PCORI; 2015-2019

DAVID VEENSTRA U24, NHGRI, Veenstra (co-PI), Jarvik G (PI) Medical Genetics UW

R01, NHGRI, Veenstra (co-PI) with Josh Peterson (Vanderbilt) and Susan Snyder (Geisinger Healthcare System)

DAVENE WRIGHT PI, Leveraging Incentives for Obesity Prevention,

2016-2018, American Heart Association

RECENT FACULTY GRANTS

23

COMPARATIVE EFFECTIVENESS RESEARCH CERTIFICATE REACHES MAJOR MILESTONE

BIOMEDICAL REGULATORY AFFAIRS PROGRAM ADDS FULL-TIME APPLIED MASTER’S DEGREE

An important change for the BRAMS program occurred this spring with the approval of our full-time Applied enroll-ment option. When the BRAMS program launched in 1998, the intended applicant pool was healthcare industry quality/regulatory professionals interested in a part-time, in-person, evening program. It soon became clear that a full-time option was necessary, both permitting students to specialize in an area of interest through additional cours-es, e.g., Chemistry, Manufacturing and Control (CMC) statistics, pharmacoepidemiology, medical biometry, and satisfying visa requirements for international students. Fourteen students graduated with a master’s degree from the BRAMS program in the 2016-17 academic year. Their practicum topics included:

CBE30 Regulatory Submission for the Acquisition of a Blood Bank

Validation Planning of the Presage Biosciences La-boratory Information Management System

Gap Analysis to Assess Compliance with the Drug Supply Chain Security Act of 2013 and 340B Drug Pricing Program

Process Definition and Template Design for Clinical Study Report Appendices

EKOS Corporation Special 510(k)

The Impact of the FDA’s Guidance on Reprocessing: A Medical Device Company’s Approach to Compli-ance

Gap Assessment of Competency Evaluation for CLIA Assays

Creation of Eye Bank Standards and SOPs for a Global Program

Creation of a Clinical Study Report Template

Evaluation and Application of the 2016 European Un-ion ‘Own Brand Labeller’ Requirement for Medical Devices

Submitting a New Drug Application Annual Report and an Orphan Drug Annual Report for an Orphan Phar-maceutical Product

Preparation of an Annual Quality Product Review for a Licensed Bulk Drug Substance at a Contract Manu-facturing Organization

Creation and Implementation of an Annual Internal Audit Program for a Good Manufacturing Practice Fa-cility

Developing a Quality Assurance Management Plan for Clinical Trials

Looking ahead, the BRAMS program is engaged in a stra-tegic planning activity that is focused on how it can be even better positioned for the future, including preparation for the 2019-2020 review by the Graduate School of all of the School of Pharmacy’s graduate programs.

This year, the Graduate Certificate in CER, led by PORPP faculty (Beth Devine, Lou Garrison, Anirban Basu) and jointly held in Health Services (Dave Grembowski, Larry Kessler) underwent the required five year review by the UW Graduate School Council. The Council commended the PORPP faculty and staff (Penny Evans) for the work invest-ed in building this program, and granted the program continuing status, with subsequent review to coincide with the academic program review of the Department of Pharmacy Gradate Program in 2019-2020. The Certificate is intend-ed for PhD students in PORPP and Health Services, and provides optional, cutting edge training in advanced CER research methods. Two of the courses have proven so popular over time that they have recently become core cours-es: Advanced Methods in CEA/CER (Josh Carlson) and Causal Inference using Observational Data (Anirban Basu). For more information visit: https://sop.washington.edu/department-of-pharmacy/pharmaceutical-outcomes-research-policy-program-porpp/certificate-programs/ for additional information. As one of six Centers of CER Excellence nationwide, originally funded by the PhRMA Foundation, PORPP faculty played a prominent role in a national invitational conference held at the Ronald Reagan Building in Washington DC in January 2017. Beth Devine served on the year-long planning committee for the conference; Lou Garrison was a featured speaker. The title of the conference was “Comparative Effectiveness and Patient-Centered Outcomes Re-search: Enhancing Uptake and Use by Patients, Clinicians and Payers”. Beth Devine is lead author on a manuscript recently submitted to the Journal of CER, which details the history of the PhRMA Foundation’s CER Centers of Ex-cellence initiative.

24